Creating a Human Anti-CD30 Antibody
Author Information
Author(s): Klimka A, Matthey B, Roovers R C, Barth S, Arends J-W, Engert A, Hoogenboom H R
Primary Institution: Laboratory of Immunotherapy, Department of Internal Medicine I, University Hospital Cologne
Hypothesis
Can a human anti-CD30 single-chain variable fragment (scFv) antibody be developed to reduce immunogenicity and improve tumor targeting?
Conclusion
The study successfully developed a human anti-CD30 scFv that shows promise for use in immunotherapeutics.
Supporting Evidence
- The study utilized phage display technology to create a human version of the Ki-4 antibody.
- The new antibody competes with the original murine antibody for binding to CD30.
- The human scFv inhibits the shedding of the CD30 receptor from cancer cells.
Takeaway
Scientists made a new human antibody that can target cancer cells better and cause fewer side effects than older treatments.
Methodology
The study used guided selection of a murine antibody combined with panning on a CD30-positive cell line to create a human scFv.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website